Reich K, et al. - In this phase 2, multicenter, double-blind trial, researchers tested the safety and effectiveness of three doses of mirikizumab (LY3074828), a p19-directed interleukin (IL)-23 antibody, vs placebo in patients with moderate-to-severe plaque psoriasis. For this investigation, study participants were randomized 1:1:1:1 to receive placebo (n = 52), mirikizumab 30 mg (n = 51), mirikizumab 100 mg (n = 51) or mirikizumab 300 mg (n = 51) subcutaneously at weeks 0 and 8. The first 16 weeks of the study were finished by 97% of patients. At week 16, 90% improvement in the Psoriasis Area and Severity Index was achieved by 67% of patients treated with 300 mg mirikizumab at 8-week intervals. In patients treated with placebo or mirikizumab, the percentage of patients reporting at least one treatment-emergent adverse event was comparable.